Somewhere between the rind of a lemon and the flesh of a sweet orange lives a molecule that most people have never heard of. Researchers have known for years that it carries antioxidant and anti-inflammatory properties. A study by Shen and colleagues published in npj Aging in 2026 found that the same compound restored a key aging gene in the liver to levels more typical of a mouse a fraction of the treated animal’s age. The finding is preliminary, still requiring much more work in humans, and has not yet been tested in clinical trials.
The molecule is hesperetin, a natural flavonoid found in lemons, limes, oranges, and other citrus fruits. It has documented antioxidant, anti-inflammatory, anti-aging, and neuroprotective properties. The new research is unusual in its specific molecular target: a longevity gene that declines with age and may be reactivated by hesperetin.
The Gene at the Center of Liver Aging
CISD2 is a longevity-associated gene that supports liver and metabolic health. Its expression decreases during aging, particularly in the liver. In the liver, CISD2 deficiency promotes steatohepatitis – a form of fatty liver disease – and hepatocellular carcinoma, the most common type of liver cancer. Increased CISD2 expression, by contrast, preserves youthful metabolic profiles and reduces age-related hepatic dysfunction, as described in a 2021 paper in Biomedicines.
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, and fatty liver disease risk increases substantially with age. The NASH subtype – nonalcoholic steatohepatitis – is where fatty liver disease turns dangerous, involving inflammation and liver damage alongside fat buildup. Left unchecked, NASH promotes liver fibrosis and some patients progress to cirrhosis or hepatocellular carcinoma. The liver performs over 500 vital functions according to Johns Hopkins Medicine – including detoxification, protein synthesis, bile production, and metabolic regulation.
What Hesperetin Did in Aged Mice
Hesperetin was identified as a CISD2 activator through herb compound library screening and showed no detectable toxicity in either in vitro or in vivo models, as established in a 2022 study published in the Journal of Biomedical Science. That safety profile, combined with its natural origin in foods that billions of people already consume, gave researchers reason to pursue it as a practical intervention.
When orally administered late in life, hesperetin enhanced CISD2 expression in aged mice, functioning mainly in a CISD2-dependent manner to reduce age-related metabolic decline, body composition changes, glucose dysregulation, and organ senescence. RNA sequencing results showed that gene expression patterns in treated animals shifted measurably back toward what a younger animal’s liver would show.
The 2026 npj Aging study by Shen and colleagues extended this work with a direct focus on liver aging. Naturally old mice, at 21 months of age, received a daily dose of hesperetin for five months. At the end of the regimen, the old mice treated with hesperetin had liver CISD2 levels comparable to those of young mice only three months old. Several other markers of liver aging and decline were also reduced, including fatty deposits, damaged liver cells, and inflammation.
A parallel experiment tested what happens when CISD2 is genetically removed from liver cells entirely. Mice engineered to lack the gene in their liver’s main functional cells already showed poor liver health at just three months of age. When those mice received hesperetin, the compound largely failed to produce the same benefits – confirming that the citrus molecule’s primary action in the liver runs through the CISD2 pathway. The researchers also noted some CISD2-independent changes, but the gene’s presence appears to be the essential condition for the bulk of hesperetin’s liver-protective effects.
The signaling pathway involved two proteins called Hmgcs2 and PPARα. Together, these proteins appear to drive the increase in CISD2 activity, giving researchers a specific molecular target for further investigation.
The Human Tissue Angle
The research team analyzed liver tissue from 80 patients who had undergone surgery for liver cancer or benign tumors – non-tumor tissue, specifically – and found that both PPARα and CISD2 expression declined with age in those human samples. This does not prove that hesperetin will produce the same restoration in a human liver that it achieved in mice. It does show that the age-related decline in CISD2 operates in human tissue, not only in rodent models.
A 2024 paper published in Biogerontology examined hesperetin’s structural interaction with CISD2 using computational immunoinformatics and found that molecular docking models support hesperetin as a CISD2 activator affecting metabolic pathways, with a specific emphasis on liver aging. That modeling work supports the biological plausibility of the effect in humans, though it is not a substitute for clinical trial data.
A Broader Pattern in Citrus Flavonoids and Liver Aging
The CISD2 pathway is not the only route through which citrus-derived flavonoids appear to benefit aging liver tissue. A 2026 study published in BioFactors examined both hesperetin and the related citrus flavanone naringenin in 24-month-old rats. Both flavanones increased protein persulfidation levels – a marker of antioxidant cellular protection – while exerting distinct effects on the hydrogen sulfide metabolic network.
Antioxidant enzyme activity, inflammation suppression, gene expression restoration, and mitochondrial support have each been documented in separate bodies of research on citrus flavonoids. The CISD2 pathway described in the 2026 npj Aging study adds a longevity-gene dimension that had not previously been connected to a dietary compound with this level of mechanistic specificity.
A comprehensive 2025 review published in Nutrition Research Reviews examined hesperetin and hesperidin across multiple liver conditions, finding that both compounds show promise as anti-inflammatory and antioxidant agents, though relatively low water solubility limits some potential effects. The review called for more studies to establish the optimum therapeutic dosage.
A 2025 study in Open Medicine applied network pharmacology to hesperetin’s effects on metabolic dysfunction-associated steatotic liver disease (MASLD – the recently updated name for NAFLD). Human tolerability has early support from a pharmacokinetic study published in the European Journal of Clinical Nutrition, in which six healthy volunteers received 135 mg of oral hesperetin under fasting conditions, establishing that the compound can be absorbed and detected in plasma. That early data represents a basic prerequisite for further clinical development, not evidence of therapeutic effect.
The liver has a unique ability to regenerate to meet the body’s metabolic needs – a trait that has long made it a target of interest for regenerative medicine. The hesperetin research raises the question of whether supporting the molecular machinery that sustains that regenerative capacity, specifically through CISD2, can extend functional liver health into old age. The gene’s role in mitochondrial maintenance and calcium regulation suggests that preserving its expression may sustain the cellular infrastructure the liver needs to keep repairing itself, though this remains to be confirmed in humans.
Read More: Popular Fiber Supplement May Not Be Suitable for Fatty Liver Disease
What This Means for You
The current state of research does not yet support taking hesperetin supplements specifically to reverse liver aging in humans. No clinical trials have tested that application, and the jump from aged mice to people involves layers of complexity that animal studies cannot resolve. Doses, delivery methods, and long-term safety in older adults all remain to be established. The human data amounts to the observation that the same gene that declines in aging mice also declines in aging human liver tissue – a correlation that justifies further investigation, not a clinical recommendation.
Hesperetin and its precursor hesperidin are found in meaningful concentrations in oranges, lemons, limes, and grapefruit. Regular citrus consumption exposes liver tissue to the compound in question – one that now has a specific, mechanistically plausible pathway linking it to liver longevity gene activity. That is not a pharmacological dose, and it is not equivalent to the controlled administration used in the mouse study.
If you have risk factors for fatty liver disease – particularly if you are over 60, have metabolic syndrome, carry excess abdominal weight, or have a family history of liver disease – the practical steps remain unchanged: reduce processed food and added sugar intake, maintain a healthy body weight, stay physically active, and have your liver enzymes checked during routine blood work. The CISD2 research provides a molecular explanation for why the liver becomes more vulnerable with age and identifies a dietary compound that has earned a place in the research pipeline as a potential tool to address that vulnerability. The clinical work needed to confirm a human benefit will take years.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.